![[FROM LEFT] Claudia Popp, Olga Tkachenko and Marta Carnielli](https://ds982gbwnvyso.cloudfront.net/Pictures/274x183/4/4/1/441_5m4a4767_toprasymposium2022_day3_20221019_816643.jpg)
On the path to adoption of decentralised clinical trials
Decentralised clinical trials (DCTs) offer great potential to improve the clinical trial paradigm, bringing more diversity and less burden to the participants we serve. COVID-19 has driven DCTs, offering greater flexibility to clinical trial patients. More needs to be done to make DCTs a standard option.
This is member-only content
To read this article, SIGN IN NOW if you are a TOPRA member.
Not a TOPRA member yet?
Join now to get access to:
- Features and specialist articles
- CPD supplements
- Comprehensive archive
Not sure yet? Read one of our free editorials to see what you’re missing out on!
The Organisation for Professionals in Regulatory Affairs
- Issues
- Contact us
- Topics A-Z
- Contributors A-Z
- © 2023 Regulatory Rapporteur